张学智;魏玮;蓝宇;

• 1:中国中医药研究促进会消化整合医学分会

摘要(Abstract)：

<正>幽门螺杆菌(helicobacter pylori, Hp)感染是胃炎最主要的致病因素和预防胃癌最重要的、可控的危险因素[1],几乎所有的Hp现症感染者均存在不同程度的胃黏膜炎症。2015年《幽门螺杆菌胃炎京都全球共识》[2]将Hp胃炎定义为感染性疾病(infectious disease),并推荐所有无制衡因素的感染者均接受根除治疗,此后诸多共识接受了这一观点。铋剂四联疗法作为根除治疗的推荐方案,依然面临抗生素耐药、不良反应风险的挑战。

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation): 北京市中医管理局中医药行业发展提质增效专项

作者(Author): 张学智;魏玮;蓝宇;

Email:

DOI: 10.13288/j.11-2166/r.2020.22.019

参考文献(References)：

• [1]国家消化系疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟(GECA),中华医学会消化病学分会幽门螺杆菌学组,等.中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年,上海)[J].中华消化杂志,2019,39(5):310-316.
• [2]SUGANO K,TACK J,KUIPERS EJ,et al.Kyoto global consensus report on Helicobacter pylori gastritis[J].Gut,2015,64(9):1353-1367.
• [3]QASEEM A,SNOW V,OWENS DK,et al.The development of clinical practice guidelines and guidance statements of the American College of Physicians:summary of methods[J].Ann Intern Med,2010,153(3):194-199.
• [4]World Health Organization.International Classification of Diseases 11th Revision [EB/OL].(2018-01-05) [2020-07-19].https://icd.who.int/browse11/l-m/en.
• [5]陈佑邦,潘筱秦,金棣生,等.中医病证分类与代码[S].北京:中国标准出版社,1995.
• [6]中华医学会消化病学分会.中国慢性胃炎共识意见(2017年,上海)[J].胃肠病学,2017,22(11):670-687.
• [7]刘文忠,谢勇,陆红,等.第五次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志,2017,56(7):532-545.
• [8]姚思敏,罗庆锋.传统胃镜下幽门螺杆菌感染表现[J].中华消化内镜杂志,2018,35(12):957-960.
• [9]胡伏莲,张声生.全国中西医整合治疗幽门螺杆菌相关“病-证”共识[J].中国中西医结合消化杂志,2018,26(9):715-723.
• [10]陈瑶,刘庆义,叶晖,等.幽门螺杆菌相关性胃病中医证型及证候要素演变规律的多中心研究[J].现代中医临床,2015,22(2):12-16.
• [11]李培彩,吴震宇,卢小芳,等.幽门螺杆菌感染相关疾病中医证候分布的文献研究[J].北京中医药,2016,35(1):21-24.
• [12]陈润花,张厂,苏泽琦,等.幽门螺杆菌相关性慢性胃炎中医证候分类研究[J].北京中医药大学学报,2014,37(3):156-159.
• [13]中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
• [14]胡伏莲,周殿元.幽门螺杆菌感染的基础与临床[M].3版.北京:中国科学技术出版社,2009:59-60.
• [15]中华中医药学会脾胃病分会.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(7):3060-3064.
• [16]刘倩,叶晖,成虹,等.HP感染根除治疗与舌象变化的相关性研究[J].北京中医药,2018,37(10):926-928.
• [17]张月苗,王婷婷,叶晖,等.荆花胃康胶丸联合三联疗法治疗幽门螺杆菌感染慢性胃炎疗效观察[J].中国中西医结合消化杂志,2013,21(11):587-590.
• [18]成虹,胡伏莲,盛剑秋,等.荆花胃康胶丸联合含呋喃唑酮三联或四联疗法补救治疗幽门螺杆菌感染的多中心随机对照研究[J].中华医学杂志,2016,96(40):3206-3212.
• [19]魏玮,杨洋.慢性萎缩性胃炎诊治现状及中医药治疗优势[J].中医杂志,2016,57(1):36-40.
• [20]国家药品监督管理局.关于修订呋喃唑酮片说明书的公告(2018年第43 号) [EB/OL].(2018-07-23) [2020-07-14].http://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_smssggg/201807/t20180723_38034.html.
• [21]国家药品监督管理局.关于停止生产销售使用含呋喃唑酮复方制剂的公告(2019年第9号)[EB/OL].(2019-02-15) [2020-07-14].http://www.gov.cn/xinwen/2019-02/15/content_5366008.htm.
• [22]王革丽,李岩.标准三联加大黄、黄连及黄芩根除幽门螺杆菌疗效的比较[J].中国中西医结合消化杂志,2015,23(12):856-858.
• [23]胡伏莲,成虹,张学智,等.多中心临床观察荆花胃康联合三联疗法治疗幽门螺杆菌相关性十二指肠溃疡和胃炎疗效及耐药分析[J].中华医学杂志,2012,92(10):679-684.
• [24]陈晓伟,裴文婧,李晓红,等.辨证论治中药联合标准三联疗法治疗Hp相关性慢性胃炎临床观察[J].时珍国医国药,2019,30(8):1931-1934.
• [25]YAO XJ,LI Y.Effect of modified Sanhuang Xiexin Tang plus additional herbs combined with “standard triple therapy” on Helicobacter pylori eradication[J].J Tradit Chin Med,2018,38(1):101-106.
• [26]汪楠,王垂杰,李玉锋.中药联合“四联疗法”治疗Hp阳性慢性胃炎疗效观察[J].中国中西医结合杂志,2017,37(4):406-409.
• [27]陈昶洲,李莉,顾志坚,等.四联疗法联合黄芪颗粒根除幽门螺杆菌的临床研究[J].胃肠病学,2014,19(8):482-485.
• [28]MARIO FD,SCIDA S,TURSI A,et al.Is the interval between the first and the second h.p.eradication therapy relevant for the success of the cure?a comparison between one week,one month and one year [J].Gastroenterology,2018,154(6):931.
• [29]张北华,唐旭东,王凤云,等.中药抗幽门螺杆菌作用机制研究进展[J].中华中医药学刊,2015,33(3):555-557.
• [30]马继征,冯硕,胡伏莲.分阶段综合治疗难治性幽门螺杆菌感染63例临床观察[J].中国中西医结合杂志,2018,38(1):20-24.
• [31]汪红兵,李帷,王薇,等.健脾清化方联合补救三联治疗耐药幽门螺杆菌感染性胃炎脾虚湿热证的临床研究[J].北京中医药,2015,34(7):536-540
• [32]潘涛,顾兴平,刘芙成,等.左金丸联合三联与铋剂四联疗法在幽门螺杆菌根除失败后补救治疗中的疗效评价[J].西部医学,2013,25(10):1516-1518.
• [33]李建勋,吕宾,杜勤,等.荆花胃康胶丸联合铋剂四联治疗幽门螺杆菌阳性慢性胃炎多中心随机对照研究[J].中国中西医结合消化杂志,2018,26(12):998-1004.
• [34]ZHANG YX,ZHOU LY,SONG ZQ,et al.Primary anti-biotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing:a prospective serial study[J].World J Gastroenterol,2015,21(9):2786-2792.
• [35]邓鑫,张学智,成虹,等.含呋喃唑酮方案治疗幽门螺杆菌感染的研究进展[J].现代药物与临床,2019,34(9):2876-2880.
• [36]LU C,SANG J,HE H,et al.Probiotic supplementation does not improve eradication rate of helicobacter pylori infection compared to placebo based on standard therapy:a meta-analysis[J].Sci Rep,2016,6:23522.doi:10.1038/srep23522.
• [37]SHI XG,ZHANG JH,MO LS,et al.Efficacy and safety of probiotics in eradicating helicobacter pylori:a network meta-analysis [J].Medicine(Baltimore),2019,98(15):e15180.doi:10.1097/MD.0000000000015180.
• [38]丰胜利,叶晖,张默,等.中药为主非抗生素疗法治疗幽门螺杆菌感染78例回顾性分析[J].北京中医药,2018,37(10):915-918.
• [39]卢美璘,张印,李绍旦,等.半夏泻心汤化裁方治疗幽门螺杆菌相关性胃炎寒热错杂证的临床研究[J].北京中医药,2019,38(5):480-483.
• [40]黄星涛,张学智,李宁,等.荆花胃康胶丸对幽门螺杆菌耐药菌株体外抑菌作用的研究[J].中国中西医结合消化杂志,2010,18(5):290-293.
• [41]曲智威,温春阳,于明俊,等.半夏泻心汤及7种单味中药对幽门螺杆菌耐药菌株的体外抑菌实验研究[J].中国中西医结合消化杂志,2015,23(8):543-546.
• [42]LOSURDO G,CUBISINO R,BARONE M,et al.Probiotic monotherapy and helicobacter pylori eradication:a syste-matic review with pooled-data analysis[J].World J Gastroenterol,2018,24(1):139-149.
• [43]CHEY WD,LEONTIADIS GI,HOWDEN CW,et al.ACG clinical guideline:treatment of helicobacter pylori infection[J].Am J Gastroenterol,2017,112:212-238.
• [44]GAO CP,ZHANG D,ZHANG T,et al.PPI-amoxicillin dual therapy for Helicobacter pylori infection:an update based on a systematic review and meta-analysis[J].Helicobacter,25(4):e12692.doi:10.1111/hel.12692.
• [45]YANG J,ZHANG Y,FAN L,et al.Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of helicobacter pylori[J].Am J Gastroenterol,2019,114(3):437-445..
• [46]LING R,HONG L,HAI YL,et al.New dual therapy for primary treatment of Helicobacter pylori infection:a prospective randomized study in Shanghai,China[J].J Dig Dis,2014,15(11):622-627.
• [47]YU L,LUO LS,LONG XH,et al.High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line helicobacter pylori therapy:a randomized trial[J].Helicobacter,2019,4(4):e12596.doi:10.1111/hel.12596.
• [48]GRAHAM DY,FISCHBACH L.Helicobacter pylori treatment in the era of increasing antibiotic resistance[J].Gut,2010,59(8):1143-1153.
• [49]MALFERTHEINER P,MEGRAUD F,O′MORAIN CA,et al.Management of helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J].Gut,2017,66(1):6-30.
• [50]TSUDA M,KATO M,ONO S,et al.Changes of dyspeptic symptom after successful eradication in helicobacter pylori-associated dyspepsia[J].Digestion,2020,101(2):165-173.
• [51]MAZZOLENI LE,SANDER GB,FRANCESCONI CF,et al.Helicobacter pylori eradication in functional dyspepsia:HEROES trial[J].Arch Intern Med,2011,171(21):1929-1936.
• [52]TACK J,TALLEY N,CAMILLERI M,et al.Functional gastrodudenal disorders.In Drossman DA,Corazziari F,Delvaux M,et al.eds.Rome III:the functional gastrointestinal disorders[M].3rd ed.McLean VA:Denon Associates Inc,2006:419-486.
• [53]KATO M,OTA H,OKUDA M,et al.Guidelines for the management of Helicobacter pylori infection in Japan:2016 Revised Edition[J].Helicobacter,2019,24(4):e12597.doi:10.1111/hel.12597.
• [54]侯理伟,史海霞,苏晓兰,等.辛开苦降法治疗慢性萎缩性胃炎的疗效的meta分析[J].中国中西医结合消化杂志,2016,24(11):832-838.
• [55]霍永利,李佃贵,马小顺.化浊解毒方对幽门螺杆菌相关性萎缩性胃炎患者胃黏膜病理的影响[J].中医杂志,2014,55(16):1383-1385.
• [56]TANG XD,ZHOU LY,ZHANG ST,et al.Randomized double-blind clinical trial of Moluodan(摩罗丹) for the treatment of chronic atrophic gastritis with dysplasia[J].Chin J Integr Med,2016,22(1):9-18.
• [57]李江,成虹,高文,等.不同中药提取物对幽门螺杆菌耐药菌株体外抗菌活性研究[J].现代中医临床,2015,22(2):21-23,28.
• [58]YU J,YE H,LI J,et al.The antibacterial activity of mass galla chinesis et camelliae fermentata on helicobacter pylori infection[J].Evid Based Complement Alternat Med,2018,1491732.doi:10.1155/2018/1491732.
• [59]徐艺,叶柏,单兆伟,等.中草药单味与复方对幽门螺杆菌抑菌作用研究[J].中国中西医结合脾胃杂志,2000,8(5):292-293.
• [60]胡伟,王红,程丽,等.蒲公英对幽门螺杆菌体外抑菌作用的实验研究[J].胃肠病学,2006,11(6):365-366.
• [61]“温胃舒或养胃舒治疗幽门螺杆菌相关性慢性胃炎和消化性溃疡”全国多中心临床研究科研协作组.温胃舒或养胃舒治疗幽门螺杆菌相关性慢性胃炎和消化性溃疡的全国多中心临床研究[J].中华医学杂志,2010,90(2):75-78.
• [62]李依洁,尹璐,瞿先侯,等.小建中胶囊联合三联疗法治疗幽门螺杆菌感染的临床疗效观察[J].中成药,2018,40(6):1443-1446.
• [63]赵娜,李岩.小建中胶囊四联疗法根除幽门螺杆菌的疗效及相关症状的改善情况[J].中国中西医结合消化杂志,2019,27(2):143-146.
• [64]张建波,赵晓东,苏琴,等.东方胃药胶囊治疗幽门螺杆菌相关性胃炎效果观察[J].解放军医药杂志,2013,25(8):15-17.
• [65]任一鸣,朱彩虹,陈健华,等.中药六味安消联合左氧氟沙星根除幽门螺杆菌疗效观察[J].中国实用医药,2010,5(8):17-18.
• [66]朱亮亮,田金徽,拜争刚,等.胃复春治疗慢性萎缩性胃炎的系统评价[J].中国循证医学杂志.2009,9(1):81-87.
• [67]LIU Y,LIN H,BAI Y,et al.Study on the relationship between Helicobacter pylori in the dental plaque and the occurrence of dental caries or oral hygiene index[J].Helicobacter,2008,13(4):256-260.
• [68]DEN HOED CM,KUIPERS EJ.Gastric Cancer:How Can We Reduce the Incidence of this Disease?[J].Curr Gastroenterol Rep,2016,18(7):34.doi:10.1007/s11894-016-0506-0.
• [69]LOH JT,GADDY JA,ALGOOD HM,et al.Helicobacter pylori adaptation in vivo in response to a high-salt diet[J].Infect Immun,2015,83(12):4871-4883.
• [70]SONG JH,KIM YS,HEO NJ,et al.High salt intake is associated with atrophic gastritis with intestinal metaplasia[J].Cancer Epidemiol Biomarkers Prev,2017,26(7):1133-1138.
• [71]郭兰伟,刘曙正,张萌,等.油炸食品摄入与胃癌及癌前病变的相关因素分析[J].中华预防医学杂志,2018,52(2):170-174.
• [72]FAHEY JW,STEPHENSON KK,WALLACE AJ.Dietary amelioration of Helicobacter infection[J].Nutr Res,2015,35(6):461-473.
• [73]FANG X,WEI J,HE X,et al.Landscape of dietary factors associated with risk of gastric cancer:A systematic review and dose-response meta-analysis of prospective cohort studies[J].Eur J Cancer,2015,51(18):2820-2832.
• [74]HU Y,WAN JH,LI XY,et al.Systematic review with meta-analysis:the global recurrence rate of Helicobacter pylori[J].Aliment Pharmacol Ther,2017,46(9):773-779.
• [75]李超,张振玉.南京地区幽门螺杆菌根除后复发的临床研究[J].胃肠病学和肝病学杂志,2019,28(8):890-894.
• [76]SARI YS,CAN D,TUNALI V,et al.H pylori:Treatment for the patient only or the whole family?[J].World J Gastroenterol,2008,14(8):1244-1247.
• [77]ZHOU LY,SONG ZQ,XUE Y,et al.Recurrence of Helicobacter pylori infection and the affecting factors:A follow-up study[J].J Dig Dis,2017,18(1):47-55.
• [78]CHOI IJ,KIM CG,LEE JY,et al.Family history of gastric cancer and helicobacter pylori treatment[J].N Engl J Med,2020,382(5):427-436.
• [79]TOYOSHIMA O,NISHIZAWA T,KOIKE K.Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis[J].World J Gastroenterol,2020,26(5):466-477.
• [80]李鲁,王红妹,沈毅.SF-36健康调查量表中文版的研制及其性能测试[J].中华预防医学杂志,2002,36(2):38-42.